Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases (2010–2013)

The project seeks to develop second generation biopharmaceuticals based on chaperonin 10 (Cpn10), which has been shown to be efficaceous in Phase IIa clinical trials for both rheumatoid arthritis and psoriasis. A series of mutants will be produced based on recent structure determination of Cpn10 and known sequence motifs, and tested in animal models of inflammatory disease including a rat collagen-induced arthritis and inflammatory bowel disease models. The development of second generation, Cpn10-based biopharmaceuticals will have applicatons over a wide variety of inflammatory diseases and will establish Cpn10 and Cpn10-based entities as a new class of anti-inflammatory agents. '',
Grant type:
ARC Linkage Projects
  • Senior Group Leader
    Australian Institute for Bioengineering and Nanotechnology
  • Director, CIPDD
    UQ Centre for Clinical Research
    Faculty of Medicine
    School of Pharmacy
    Faculty of Health and Behavioural Sciences
    Affiliate Professor
    Institute for Molecular Bioscience
  • NHMRC Career Development Fellow
    School of Biomedical Sciences
    Faculty of Medicine
Funded by:
Australian Research Council